Morse Michael A, Clay Tim, Colling Kirsten, Lyerly H Kim
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Mol Biotechnol. 2003 Sep;25(1):95-9. doi: 10.1385/MB:25:1:95.
Dendritic cell-based vaccines are being evaluated in clinical trials to determine their ability to activate clinically relevant tumor antigen-specific immune responses. Although some groups isolate dendritic cells from peripheral blood, most have found it more efficient to generate large numbers from peripheral blood progenitors, particularly plastic adherent or CD14+ monocytes, in media supplemented with GM-CSF and IL-4. These DC may then be matured, if desired, and loaded with antigen, such as tumor-associated peptides, prior to administration. We describe the scheme that we are currently using to generate peptide-loaded dendritic cells for our clinical trials of cancer immunotherapy.
基于树突状细胞的疫苗正在临床试验中进行评估，以确定其激活临床相关肿瘤抗原特异性免疫反应的能力。尽管一些研究小组从外周血中分离树突状细胞，但大多数人发现，在添加粒细胞-巨噬细胞集落刺激因子（GM-CSF）和白细胞介素-4（IL-4）的培养基中，从外周血祖细胞，特别是塑料贴壁细胞或CD14+单核细胞中大量生成树突状细胞更有效。然后，如果需要，这些树突状细胞可以成熟，并在给药前加载抗原，如肿瘤相关肽。我们描述了我们目前用于为癌症免疫治疗临床试验生成肽负载树突状细胞的方案。
